Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

A pheochromocytoma is a type of tumor found in the adrenal glands or certain nerve cells. These tumors are very rare but can cause dramatic symptoms because they tend to secrete large amounts of ...

Another original article (Liu et al.) focused on the evaluation of postoperative management of patients with pheochromocytoma assessing hemodynamic stability as one of the main causes of serious ...

In this study, CHB and RCC were still the leading causes of deaths in VHL patients ... renal cell carcinoma; PHEO, pheochromocytoma; PCL/PNET, pancreatic cystic lesion and pancreatic neuroendocrine ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...

Possible causes of low blood pressure, or hypotension, range from dehydration to a heart condition. Drinking more water may help, but some people will need medication. Changing dietary habits may ...